Literature DB >> 2479277

The interferon system in subacute sclerosing panencephalitis and its response to isoprinosine.

N Gadoth1, E Kott, S Levin, T Hahn.   

Abstract

Plasma interferon activity (IFN) and its spontaneous and stimulated production by peripheral blood mononuclear cells (PBMC) was studied in 11 patients with subacute sclerosing panencephalitis (SSPE) and age-matched healthy controls. The patients, similar to the healthy controls, had no detectable plasma IFN activity. However, their PBMC failed to produce IFN in response to stimulation with poly I:C and PHA. After isoprinosine administration to 7 patients for several days a significant increase in plasma IFN activity was observed and their PBMC responded to stimulation by producing IFN. The long-term effect of isoprinosine on the IFN response was evaluated in 3 patients who had been treated for 57-88 days. Induction of the abolished IFN production was observed with initiation of therapy. However, discontinuation of isoprinosine for 10 days resulted in recurrence of the inactivation state of the IFN system.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2479277     DOI: 10.1016/s0387-7604(89)80058-0

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  2 in total

1.  Subacute Sclerosing Panencephalitis in Children: The Archetype of Non-Vaccination.

Authors:  Laura Papetti; Maria Elisa Amodeo; Letizia Sabatini; Melissa Baggieri; Alessandro Capuano; Federica Graziola; Antonella Marchi; Paola Bucci; Emilio D'Ugo; Maedeh Kojouri; Silvia Gioacchini; Carlo Efisio Marras; Carlotta Ginevra Nucci; Fabiana Ursitti; Giorgia Sforza; Michela Ada Noris Ferilli; Gabriele Monte; Romina Moavero; Federico Vigevano; Massimiliano Valeriani; Fabio Magurano
Journal:  Viruses       Date:  2022-03-31       Impact factor: 5.818

2.  Subacute sclerosing panencephalitis : diagnosis and drug treatment options.

Authors:  B Anlar
Journal:  CNS Drugs       Date:  1997-02       Impact factor: 5.749

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.